Sat.Nov 19, 2022 - Fri.Nov 25, 2022

article thumbnail

The 340B program is interfering with the U.S. biosimilars market and impacting patient costs

PhRMA

Research has shown that 340B hospitals are more likely to prescribe more expensive medicines and significantly mark up the price of medicines. For example, 340B hospitals received nearly five times what they paid, on average, to acquire oncology medicines through 340B. These practices have implications for what patients pay out of pocket — and new research adds to the evidence.

Hospitals 262
article thumbnail

Juvenile Idiopathic Inflammatory Myopathies Following COVID-19 Infection

Drug Topics

In a recent study, racial minorities of an older age with non-classic cutaneous manifestations were more often to present with juvenile idiopathic inflammatory myopathies after COVID-19 infection.

188
188
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

AI will continue to attract investment in near future in the healthcare industry

Pharmaceutical Technology

Artificial intelligence (AI) was seen as one of the top current investment priorities and was thought to continue to attract investment in the healthcare sector in the upcoming two years, according to GlobalData's latest report ‘Digital Transformation and Emerging Technology in the Healthcare Industry - 2022 Edition’. In this survey-based report tracker, digital media was prioritised as a top current investment target, with 53% of surveyed respondents confirming that their companies are currentl

article thumbnail

Opinion: A tripledemic hurricane is making landfall. We need masks, not just tent hospitals

STAT

A viral hurricane is making landfall on health care systems battered by three pandemic years. With the official start of winter still weeks away, pediatric hospitals are facing crushing caseloads of children sick with RSV and other viral illnesses. Schools that promised a “return to normal” now report widespread absences and even closures from RSV and flu in many parts of the country , contributing to parents missing work in record numbers.

Hospitals 145
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

How HTA-based price controls could worsen health outcomes and health disparities

PhRMA

Concerns about the cost of health care have led to calls for the use of health technology assessments or HTAs by the federal government. This would allow government agencies to make important decisions about patient access to health care based on their determination of the value of new tests and treatments.

192
192
article thumbnail

Research Examines Link Between Vitiligo and Systemic Sclerosis

Drug Topics

Israeli researchers find more than fivefold risk of developing systemic sclerosis among people with vitiligo.

209
209

More Trending

article thumbnail

Real-world data show updated Covid-19 boosters increase protection against infection

STAT

The updated Covid-19 boosters increase people’s protection against symptomatic infection from the coronavirus, according to some of the first estimates of how the shot is performing in the real world and in people, not just in lab experiments. What’s more, that protection was even stronger when people waited a longer period of time since their last dose of the original shot.

Vaccines 138
article thumbnail

Putting Delaware patients first: Protecting Patient Assistance Programs

PhRMA

Patients with chronic health conditions in Delaware are seeing a new wave of relief thanks to Governor John Carney, members of the Delaware legislature and more than 40 patient groups. The recently passed SB267 will make it easier for vulnerable patients to be able to afford their brand medications.

162
162
article thumbnail

Best of COVID-19 Coverage in 2022

Drug Topics

Take a look back at our most popular COVID-19 coverage for 2022.

201
201
article thumbnail

Multiple SARS-CoV-2 Infections May Elevate Risk of Organ Failure, Death

Pharmacy Times

Individuals with COVID-19 reinfections were twice as likely to die and three times more likely to be hospitalized than those who did not have COVID-19 multiple times.

Hospitals 139
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

STAT+: FDA approves a gene therapy for the inherited bleeding disorder hemophilia B

STAT

The Food and Drug Administration on Tuesday approved the first gene therapy to treat people with hemophilia B, an inherited bleeding disorder. The one-time treatment, called Hemgenix, was developed by the Dutch biotech company UniQure and will be marketed by CSL Behring, an Australian pharmaceutical company.

article thumbnail

FDA approves first gene therapy for Haemophilia B

European Pharmaceutical Review

The US Food and Drug Administration (FDA) has approved Hemgenix (etranacogene dezaparvovec), the first gene therapy for adults with Haemophilia B (congenital Factor IX deficiency) who currently use Factor IX prophylaxis therapy, or have current or historical life-threatening haemorrhage, or have repeated, serious spontaneous bleeding episodes. Standard treatment for the condition involves replacing the missing or deficient clotting factor to improve the body’s ability to stop bleeding and promot

FDA 126
article thumbnail

Best of Diabetes Coverage in 2022

Drug Topics

Take a look back at our most popular diabetes coverage for 2022.

201
201
article thumbnail

Workplace Stress Was Highest Among Younger Employees During COVID-19 Pandemic

Pharmacy Times

Study finds early career workers were more likely to disengage during the pandemic, such as by showing a lack of interest or becoming cynical about work.

145
145
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Experimental flu vaccine, developed using mRNA, seen as potential game changer

STAT

An experimental influenza vaccine developed using messenger RNA technology appears capable of inducing what should be a protective immune response against all known subtypes of flu, at least in animals. If the work is translated into humans it could turn out to be a version of a long-sought universal vaccine. This would not be a vaccine that would block all flu infections, nor would it replace the need for an annual flu shot.

Vaccines 132
article thumbnail

Taking the right forecasting approach for rare diseases

pharmaphorum

There are approximately 7,000 different types of rare disease and researchers estimate that there are more than 300 million people worldwide living with such a condition, according to the National Institutes of Health (NIH). However, only 5% of rare diseases are estimated to have at least one approved treatment, known as “orphan” therapies. A rare disease is any disease that affects a small percentage of the population.

article thumbnail

First-in-human gene therapy trial for major cardiac syndrome

European Pharmaceutical Review

The first-in-human gene therapy trial for heart failure patients with preserved ejection fraction (HFpEF) has been approved by the US Food & Drug Administration (FDA). SRD-001, the adenovirus associated virus (AAV)-based gene therapy is delivered to cardiac ventricular muscle cells via an intracoronary infusion system (produced by Sardocor, a clinical-stage gene therapy subsidiary of Medera), to increase the protein expression and functional activity of sarcoplasmic reticulum calcium ATPase

Labelling 125
article thumbnail

5 Hot Topics for Community Pharmacists in 2023

Pharmacy Times

As a new year approaches, pharmacists have so much to look back on and be grateful for, and a world of opportunity in front of them. Here are a few things to be ready for right away in 2023.

131
131
article thumbnail

Why doesn’t the U.S. have at-home flu tests?

STAT

Flu season is underway. RSV is putting record numbers of children in hospitals. And health professionals are gearing up for another Covid winter. With so many potential viruses in play, it would be helpful if Americans had a way to distinguish between different ailments at home. And when it comes to the flu in particular, at-home testing could help telehealth doctors decide when it makes sense to prescribe treatments like Paxlovid and Tamiflu, which need to be administered within a specific time

Hospitals 118
article thumbnail

FDA starts speedy review of Takeda’s dengue vaccine

pharmaphorum

The US regulator has started a priority, six-month review of Takeda’s dengue fever vaccine TAK-003 – tipped as a potential blockbuster product – making a decision likely in the first half of 2023. The Japanese pharma said it has filed for approval of TAK-003 with the FDA for the prevention of dengue disease caused by any dengue virus serotype in individuals aged four through 60.

Vaccines 122
article thumbnail

Antibiotic Exposure Linked to Increased Risk of Type 2 Diabetes Later in Life

Drug Topics

European research examines antibiotic exposure and its potential impact on future type 2 diabetes risk.

131
131
article thumbnail

Growing Need for Mental Health Care Straining Existing Resources

Pharmacy Times

Demand for treatment of anxiety and depression remained high for the third consecutive year as the demand for the treatment of trauma- and stressor-related and substance use disorders has increased.

123
123
article thumbnail

CVS Health investing $6.2M in affordable housing in Kansas, $14.3M in Washington

Drug Store News

CVS Health is investing $6.2 million to build 36 new affordable housing units in Bel Aire, Kan., and $14.3 million to build 120 affordable housing units in Seattle, Wash.

116
116
article thumbnail

Ex-Theranos CEO Elizabeth Holmes sentenced to 11 years

pharmaphorum

Elizabeth Holmes, the founder and former chief executive of blood testing biotech Theranos, has been sentenced after being convicted of defrauding investors in the company earlier this year, receiving a prison sentence of more than 11 years in a California court. That’s shorter than the 15 years sought by prosecutors, but considerably longer than the 18 months’ house arrest that Holmes’ defense attorneys had pushed for, and there is likely to be an appeal against the sentence,

FDA 122
article thumbnail

Ozempic compensating for Wegovy’s supply shortage due to high demand

Pharmaceutical Technology

In recent months, Wegovy (semaglutide), indicated for obesity, has been subjected to widespread supply shortages due to high demand, in addition to manufacturer production problems, with Novo Nordisk intending to relaunch Wegovy by the end of 2022. In the meantime, however, Novo Nordisk’s Ozempic, another version of semaglutide indicated particularly for patients with type 2 diabetes, has picked up the slack by being used off-label for obesity patients.

Labelling 111
article thumbnail

Study: Significant New Onset Morbidity Observed in Children, Adolescents, Adults Following COVID-19 Infection

Pharmacy Times

Although long-term health issues from COVID-19 are a major public health concern, evidence on post-acute COVID-19 syndrome, or post-COVID-19, is still limited, specifically among children and adolescents.

123
123
article thumbnail

How infectious disease experts are responding to Covid nearly three years in

STAT

The world is fast approaching the third anniversary of those days when we got our first inkling that a new disease was spreading in China. In the months that followed, normal life was suspended, then upended. At this point, everyone is well and truly sick of Covid-19 and the accommodations we have had to make to co-exist with it. So sick of it, in fact, that many people appear to have given up trying to avoid the SARS-CoV-2 virus.

105
105
article thumbnail

Provention prices type 1 diabetes drug Tzield at $194,000

pharmaphorum

Provention Bio has priced its new type 1 diabetes (T1D) prevention therapy Tzield at $13,850 per vial – equivalent to almost $194,000 for its 14-day course – a higher level than had been predicted by industry observers. The company argues that the cost is justified as Tzield (teplizumab) is the first drug that can delay the onset of type 1 diabetes, fending off the time when they become highly reliant on insulins and at risk of the serious complications that can accompany advanced T1D.

Insurance 116
article thumbnail

NICE questions value and efficacy of five Covid-19 drugs with rejection

Pharmaceutical Technology

The UK's National Institute for Health and Care Excellence (NICE) has published a draft guidance that does not recommend the use of five major Covid-19 therapies. This news came as many organisations and patient advocacy groups have been campaigning for the adoption of some of the rejected drugs for several months, amidst concerns about access to medicines in the UK.

Hospitals 111
article thumbnail

Pharmacist Publishes Children’s Book About Getting Your Flu Shot

Pharmacy Times

Our Best Shot (OBS) is a new children’s book explaining why we should get an annual flu shot and it is not something to fear…and adults may even benefit, said the author.

121
121
article thumbnail

Google rolls out search features that aim to make it easier to sign up for Medicaid, Medicare

Fierce Healthcare

Google rolls out search features that aim to make it easier to sign up for Medicaid, Medicare. pminemyer. Wed, 11/23/2022 - 11:12.

126
126
article thumbnail

Why should pharma invest in digital products for those living with rare diseases?

pharmaphorum

Each person living with a rare disease has a unique experience of their condition, but all will have faced similar challenges. They have suffered from an overwhelming diagnosis experience that has left them feeling misunderstood, isolated, and desperate for someone to help them connect symptoms and make sense of the sheer volume of information. Many will also face barriers to care, where access to specialists is limited and often geographically out of reach.

article thumbnail

Umoja and IASO partner to develop therapies for haematological malignancies

Pharmaceutical Technology

Umoja Biopharma has signed a research agreement with IASO Biotherapeutics (IASO Bio) to develop off-the-shelf therapies for haematological malignancies. Under the alliance, the companies will assess the induced cytotoxic innate lymphocytes (iCIL) platform of Umoja with chimeric antigen receptors (CARs) of IASO to develop the next generation of widely accessible, easily available cell therapies.

110
110
article thumbnail

How a Large Health System Brought All Facilities Into Compliance With Updates to USP Chapters , Before Enforcement Date

Pharmacy Times

Melanie Galvin, PharmD, BCSCP, explains how Northwell Health implemented changes to bring the health system up-to-date with the revisions to USP chapters and.

123
123